Ongoing Phase 2 study in metastatic colorectal cancer (mCRC) demonstrates early clinical and biomarker activity with leronlimab in combination ...

Immune cells expressing the receptor CCR5 are recruited to areas of inflammation by chemokine ligands, making CCR5 an attractive therapeutic target for preventing cell trafficking during conditions ...

A 32-bp deletion in this gene (CCR5-Δ32 mutation) results in a nonfunctioning receptor that is trapped in the endoplasmic reticulum and therefore not expressed at the cell surface. 19, 20 The mutation ...

VANCOUVER, Washington, Feb. 20, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized ...

The past 6 months have been difficult for the developers of CCR5 antagonists. First, GlaxoSmithKline halted Phase III studies of aplaviroc because of serious hepatotoxicity (ACC Sep 28 2005), and then ...

The study evaluated Leronlimab, an investigational antibody, in combination with standard therapies TAS-102 and Bevacizumab, a targeted therapy that blocks tumor growth. ・The study showed positive ...

In a recent study published in the Clinical Infectious Diseases journal, researchers assessed the impact of long coronavirus disease 2019 (COVID-19) on C-C chemokine receptor-5 (CCR5) and ...

An HIV patient in Oslo has been in remission for the past five years following a stem cell transplant from his brother, who ...

CCR5 Antagonists Market in HIV & Rare Inflammatory Conditions to Reach $300 Million by 2025, Driven by Expanding Clinical Pipeline and Indication Diversification The global CCR5 antagonists market ...

Two pieces of news have gripped the medical science community over the last few weeks. The first is that of the scientist He Jiankui producing genetically engineered twins that were resistant to HIV ...

Translational study in metastatic triple-negative breast cancer (mTNBC) shows leronlimab-mediated CCR5 inhibition induces PD-L1 expression, ...